https://www.onclive.com/view/jak-inhibitor-based-combos-and-mutation-specific-regimens-comprise-the-future-of-myelofibrosis-management
It won't be long now till the scientific community to our advertising for us, should be a hell of a ride.
Here's a recent interview with Claire Harrison, MD, FRCP, FRCPath. She was the one who accompanied Gary in the recent interim data webinar at ASH 2024.
Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis, page-59
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
5.0¢ |
Change
-0.001(1.96%) |
Mkt cap ! $81.24M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.2¢ | 5.0¢ | $128.2K | 2.513M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 299544 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 654875 | 3 |
View Market Depth
| Last trade - 12.36pm 30/06/2025 (20 minute delay) ? |
| SNT (ASX) Chart |